We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
PAZOPANIB DR. (Dr Reddys Laboratories Australia Pty Ltd)
Product name
PAZOPANIB DR.
Date registered
Evaluation commenced
Decision date
Approval time
146 (255 working days)
Active ingredients
pazopanib hydrochloride
Registration type
New generic medicine
Indication
[TRADENAME] is indicated for the treatment of:
- Advanced and/or metastatic renal cell carcinoma (RCC).
- Advanced (unresectable and/or metastatic) soft tissue sarcoma (STS) in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment.
- The Phase III trial population excluded patients with gastrointestinal stromal tumour (GIST) or adipocytic soft tissue sarcoma.